SLC22A2 and cancer: The results of immunohistochemistry indicated the following cancer cell expression: prostate-specific antigen (PSA)-positive, prostate-specific acid phosphatase-positive, CR-negative, CD99-negative, prostate inhibin peptide-negative, erythroblast transformation-specific-related gene (ERG)-negative, placental alkaline phosphatase (PLAP)-negative, CD117 weakly positive, SA114-negative, organic cation transporter 2 (OCT2)-negative, and Ki-67 > 40% positive.